Skip to main content

Conference Correspondent

ACR 2017, Conference Correspondent

Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment

ACR 2017, Conference Correspondent

Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs

ACR 2017, Conference Correspondent

Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis

ACR 2017, Conference Correspondent

Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA

ACR 2017, Conference Correspondent

An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA

ACR 2017, Conference Correspondent

Active Treatment Leads to Improved Myocardial Function in Patients with Active RA

ACR 2017, Conference Correspondent

Suboptimal EHR Reporting of Clinical Measures in RA Patients Receiving a Biologic or Targeted Synthetic DMARD

ACR 2017, Conference Correspondent

Both Tofacitinib and Baricitinib in Combination with Methotrexate Are Efficacious in Patients with RA

ACR 2017, Conference Correspondent

No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

1
2
3
4
5

Page 2 of 8
Results 11 - 20 of 80